BCL2 and breast carcinoma: Palit et al. experimented with HSP (20–200μM) on MCF-7, MCF-10A, HMEC, MDA-MB 231 breast carcinoma and stated this compound is associated with increasing ROS production, release cyto-C, Bax/Bcl-2 ratio, caspase-9,-3, 7, PARP cleavage, JNK, and sk1activation, and activating ASK1/JNK pathway [62].